Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A.
Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgartten FJ, Schoenfelder G. · 2010
Read Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. by Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgartten FJ, Schoenfelder G. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2920080.txt.
Introduction
Vandenberg and co-authors weighed in 2010 a puzzle about bisphenol A. The chemical is produced in huge volume for plastics and can linings. Blood studies find it everywhere, yet metabolism studies say it should vanish fast. Over eighty biomonitoring studies covering thousands of people in several countries overwhelmingly detected BPA in urine, blood, and tissues of adults and children.
The active, unprocessed form appeared routinely in blood at measurable levels. Two careful toxicokinetic studies, by contrast, predicted swift processing and excretion after oral doses, implying blood levels should be near zero. The review tests explanations for the clash, from non-food exposure routes and skin contact to slow release from body stores, and finds the discrepancy unresolved. Exposure science must settle it before health risk can be judged.
Catalog record
| CREATOR | Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgartten FJ, Schoenfelder G. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 106 KB |
| LICENSE | CC0 1.0 Universal |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Urinary, Circulating, and Tissue Biomonitoring Studies Indicate Widespread Exposure to Bisphenol A By Laura N Vandenberg, Ibrahim Chahoud, Jerrold J Heindel, Vasantha Padmanabhan, Francisco JR Paumgartten, Gilbert Schoenfelder Published in: Environmental Health Perspectives DOI: 10.1289/ehp.0901716 ABSTRACT Abstract Background Bisphenol A (BPA) is one of the highest-volume chemicals produced worldwide, and human exposure to BPA is thought to be ubiquitous. Thus, there are concerns that the amount of BPA to which humans are exposed may cause adverse health effects. Importantly, results from a large number of biomonitoring studies are at odds with the results from two toxicokinetic studies. Objective We examined several possibilities for why biomonitoring and toxicokinetic studies could come to seemingly conflicting conclusions. Data sources We examined > 80 published human biomonitoring studies that measured BPA concentrations in human tissues, urine, blood, and other fluids, along with two toxicokinetic studies of human BPA metabolism. Data extraction and synthesis The > 80 biomonitoring studies examined included measurements in thousands of individuals from several different countries, and these studies overwhelmingly detected BPA in individual adults, adolescents, and children. Unconjugated BPA was routinely detected in blood (in the nanograms per milliliter range), and conjugated BPA was routinely detected in the vast majority of urine samples (also in the nanograms per milliliter range). In stark contrast, toxicokinetic studies proposed that humans are not internally exposed to BPA. Some regulatory agencies have relied solely on these toxicokinetic models in their risk assessments. Conclusions Available data from biomonitoring studies clearly indicate that the general population is exposed to BPA and is at risk from internal exposure to unconjugated BPA. The two toxicokinetic studies that suggested human BPA exposure is negligible have significant deficiencies, are directly contradicted by hypothesis-driven studies, and are therefore not reliable for risk assessment purposes. Keywords: endocrine disruptor, human exposure, PBPK/PBTK model, pregnancy, risk assessment, toxicokinetics Bisphenol A (BPA) is one of the highest volume chemicals produced worldwide, with > 8 billion pounds produced each year and > 100 tons released into the atmosphere by yearly production. Data from multiple sources indicate that the amount of BPA to which humans are exposed may cause adverse health effects; this has raised concerns among regulatory agencies all over the world. As an essential component of polycarbonate plastic, BPA is found in numerous consumer products, including baby bottles, reusable water bottles, reusable food containers, polyvinyl chloride stretch films, papers, and cardboards (reviewed by Vandenberg et al. 2007). Metallic food and beverage cans are protected from rusting and corrosion by the application of epoxy resins as inner coatings. The synthesis of many of these resins requires the condensation of BPA with epichlorohydrin to create BPA diglycidyl ether. When incomplete polymerization occurs, residual BPA leaches from the epoxy resin. High temperatures and exposure to acidic or basic solutions can also increase leaching of BPA from coatings and plastics, even when complete polymerization has occurred. More than 10 studies have detected BPA leaching from the linings of metal cans into foods (Vandenberg et al. 2007). BPA has also been detected in a variety of environmental samples, including water, sewage leachates, indoor and outdoor air samples, and dust (Vandenberg et al. 2007). It is also found in papers and in implanted medical devices and other medical equipment (Welshons et al. 2006). BPA attracted the attention of regulatory agencies and scientists in dozens of countries because of its estrogenic properties in vitro and in vivo and the conserved role that estrogen plays in regulating human and animal physiology and pathophysiology (Dodds and Lawson 1936; Markey et al. 2001; Wetherill et al. 2007). Biochemical assays have examined the kinetics of BPA binding to the estrogen receptors (ERs) and have determined that BPA binds both ERα and ERβ, with approximately 10 times higher affinity for ERβ (Gould et al. 1998; Kuiper et al. 1998). Until recently, BPA was considered a weak environmental estrogen because of its relatively low affinity for the nuclear ERs compared with estradiol in some assays (Andersen et al. 1999; Fang et al. 2000). However, results from several studies have revealed that BPA can stimulate rapid cellular responses at very low concentrations, below the levels where BPA is expected to bind to the classical nuclear ERs (Welshons et al. 2006). BPA has also been shown to bind to a membrane-associated ER and produce nongenomic steroid actions (Wetherill et al. 2007) with the same efficacy and potency as estradiol (Alonso-Magdalena et al. 2005; Hugo et al. 2008). Whatever the mechanism, BPA can cause effects in animal models at doses in the range of human exposures, indicating that it can act at lower doses than predicted from some in vitro and in vivo assays (Richter et al. 2007; Vandenberg et al. 2007; vom Saal et al. 2007; Wetherill et al. 2007). For risk assessment, a reference dose (RfD) is calculated as an acceptable daily human intake, typically 100-fold less than the no observed adverse effect level (NOAEL). However, the RfD for BPA (50 μg/kg/day) was calculated using the lowest observable adverse effect level (LOAEL) and 1,000-fold safety factors because a NOAEL had not been determined (Welshons et al. 2003). More than 150 published studies describe BPA effects in animals exposed to < 50 mg/kg/day, including altered development of the male and female reproductive tracts, organization of sexually dimorphic circuits in the hypothalamus, onset of estrus cyclicity and earlier puberty, altered body weight, altered organization of the mammary gland, and cancers of the mammary gland and prostate; > 40 of these studies examined doses less than the RfD (Richter et al. 2007). Many of these end points are in areas of current concern for human epidemiological trends (Soto et al. 2008; Vandenberg et al. 2009). Indeed, it has been suggested that exposure to xenoestrogens such as BPA during early development may be a major contributing factor to the increased incidence of infertility, genital tract abnormalities, obesity, attention deficit hyperactivity disorder, infertility, and prostate and breast cancer observed in European and U.S. human populations over the last 50 years (Sharpe and Skakkebaek 1993; Soto et al. 2008). There is great concern about exposure of human fetuses, infants, and neonates to BPA because of the sensitivity of the developing organs and brain to exogenous hormones (Vandenberg et al. 2009). However, for translating the findings from animal studies to health risks of environmental exposures to humans, exposure assessment from biomonitoring of BPA in different populations is essential. In this review, we examined > 80 biomonitoring studies that measured BPA concentrations in human tissues and fluids, specifically focusing on individuals that were exposed to BPA via their environment (i.e., nonoccupational exposures). These studies, examining thousands of individuals from several different countries, overwhelmingly detected BPA in individual adults, adolescents, and children. Interestingly, results from the large body of research encompassing biomonitoring studies are at odds with the results from two toxicokinetic studies that determined the disposition of BPA in humans after oral administration of BPA (Volkel et al. 2002, 2005). Volkel et al. (2002) reported that after oral absorption, BPA was promptly metabolized in the liver and intestines. However, findings from the > 80 biomonitoring studies we reviewed support the hypothesis that hepatic metabolism of BPA or its presystemic clearance is not 100% efficient, because unconjugated BPA